Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Raltegravir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 754Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lupin receives tentative FDA approval for Raltegravir tablets
    Lupin receives tentative FDA approval for Raltegravir tablets

    11 Nov 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/lupin-receives-tentative-u-s-fda-approval-for-raltegravir-tablets/

    EXPRESSPHARMA
    11 Nov 2024
    Share Share
    Generic HIV raltegravir medicines approved
    Generic HIV raltegravir medicines approved

    22 Jul 2024

    // EUROPEAN PHARMACEUTICAL REVIEW

    https://www.europeanpharmaceuticalreview.com/news/231638/generic-hiv-raltegravir-medicines-approved/

    EUROPEAN PHARMACEUTICAL REVIEW
    22 Jul 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Raltegravir Potassium Tablets
    FDA Confirms Paragraph IV Patent Litigation for Raltegravir Potassium Tablets

    14 Dec 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-raltegravir-potassium-tablets-92868.pdf

    FDA
    14 Dec 2022
    Share Share
    Roche, Merck, Novartis and others hike prices on 83 meds starting in July
    Roche, Merck, Novartis and others hike prices on 83 meds starting in July

    10 Jul 2019

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/roche-merck-novartis-and-others-raise-prices-83-meds-to-start-july-analyst?utm_source=internal&utm_medium=rss

    Eric Sagonowsky FIERCE PHARMA
    10 Jul 2019
    Share Share
    US FDA approves Merck's once-daily dose of Isentress in combo
    US FDA approves Merck's once-daily dose of Isentress in combo

    30 May 2017

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=102267&sid=2

    PHARMABIZ
    30 May 2017
    Share Share
    Merck shops for hefty M&A amid 'uninspiring' Q1 for new meds
    Merck shops for hefty M&A amid 'uninspiring' Q1 for new meds

    05 May 2016

    // Tracy Staton FIERCE PHARMA

    http://www.fiercepharma.com/pharma/merck-shops-for-hefty-m-a-amid-uninspiring-q1-for-new-meds

    Tracy Staton FIERCE PHARMA
    05 May 2016
    Share Share